FDA Adverse Event Injury Summary report: N

DURASEAL SEALANT SYSTEM 5ML (QTY 5) US

MDR report key: 1582054 · Received January 14, 2010

Report

Report Number
3003157248-2010-00001
Event Type
Injury
Date Received
January 14, 2010
Report Date
December 18, 2009
Manufacturer
CONFLUENT SURGICAL,INC
Product Code
NQR
PMA / PMN Number
P040034
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
OH, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

ON 01/14/2010, THE SURGEON REPORTED THAT "THE PATIENT'S PROGNOSIS IS FAIR. SHE HAS RESIDUAL DEFECTS BUT THEY HAVE IMPROVED SINCE THE SECOND SURGERY." THE DHR REVIEW CONFIRMED THAT LOT C070695-01 MET THE REQUIRED SPECIFICATIONS AT LOT RELEASE. NOTE: SWELLING OF THE DURASEAL IS A NORMAL CONDITION. THE DURASEAL IFU, LISTS THE FOLLOWING CONTRAINDICATION: "DO NOT APPLY THE DURASEAL HYDROGEL TO CONFINED BONY STRUCTURES WHERE NERVES ARE PRESENT SINCE NEURAL COMPRESSION MAY RESULT DUE TO HYDROGEL SWELLING. THE HYDROGEL MAY SWELL UP TO 50% OF ITS SIZE IN ANY DIMENSION."

Description of Event or Problem · 1

ACCORDING TO THE REPORTER, THE SURGEON HAD A RECENT UNSATISFACTORY EXPERIENCE WITH DURASEAL. THE CASE WAS A T3 LAMINECTOMY TO PLACE A SHUNT INTO THE SPINAL CORD. THE DURA WAS SUTURED CLOSED. THE SURGEON APPLIED DURASEAL AND BELIEVED THE THICKNESS TO BE A FEW MMS. THE SURGERY OCCURRED AND THE PATIENT WAS DISCHARGED POST-OP DAY TWO. THE PATIENT WENT TO ER AFTER EXPERIENCING SOME PARALYSIS. INITIAL DIAGNOSIS WAS A POTENTIAL HEMATOMA. THE PATIENT UNDERWENT A RE-OPERATION. THE SURGEON STATED THAT THE ORIGINAL DURASEAL TREATED AREA CONTAINED A CLEAR, GELATIN-LIKE MATERIAL WHICH WAS 10+ MM THICK. HE ATTRIBUTED THE GELATIN-LIKE MATERIAL TO DURASEAL. THE MATERIAL WAS REMOVED. THE PATIENT RECOVERED SOME MOBILITY, BUT MAY STILL EXPERIENCE PARTIAL PARAPLEGIA.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 DURASEAL SEALANT SYSTEM 5ML (QTY 5) US DURAL SEALANT NQR NQR CONFLUENT SURGICAL,INC C070695-01

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention